vs
ABEONA THERAPEUTICS INC.（ABEO）与碧迪（BDX）财务数据对比。点击上方公司名可切换其他公司
碧迪自由现金流更多（$549.0M vs $-23.7M）
Abeona Therapeutics是一家临床阶段生物制药公司，专注于研发针对致命罕见遗传病的创新基因与细胞疗法，其管线覆盖多种未被满足的临床需求，主要为北美、欧洲地区缺乏有效治疗方案的患者群体服务。
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
ABEO vs BDX — 直观对比
营收规模更大
BDX
是对方的Infinity倍
$0
自由现金流更多
BDX
多$572.7M
$-23.7M
损益表 — Q3 2025 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $0 | $5.3B |
| 净利润 | $-5.2M | $382.0M |
| 毛利率 | — | 45.9% |
| 营业利润率 | — | 10.5% |
| 净利率 | — | 7.3% |
| 营收同比 | — | -0.4% |
| 净利润同比 | 82.9% | 24.0% |
| 每股收益（稀释后） | $-0.10 | $1.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABEOBDX
| Q4 25 | — | $5.3B | ||
| Q3 25 | $0 | $5.9B | ||
| Q2 25 | $400.0K | $5.5B | ||
| Q1 25 | — | $5.3B | ||
| Q4 24 | — | $5.2B | ||
| Q3 24 | — | $5.4B | ||
| Q2 24 | — | $5.0B | ||
| Q1 24 | — | $5.0B |
净利润ABEOBDX
| Q4 25 | — | $382.0M | ||
| Q3 25 | $-5.2M | $493.0M | ||
| Q2 25 | $108.8M | $574.0M | ||
| Q1 25 | — | $308.0M | ||
| Q4 24 | — | $303.0M | ||
| Q3 24 | — | $400.0M | ||
| Q2 24 | — | $487.0M | ||
| Q1 24 | — | $537.0M |
毛利率ABEOBDX
| Q4 25 | — | 45.9% | ||
| Q3 25 | — | 47.5% | ||
| Q2 25 | — | 47.8% | ||
| Q1 25 | — | 42.8% | ||
| Q4 24 | — | 43.2% | ||
| Q3 24 | — | 45.7% | ||
| Q2 24 | — | 46.2% | ||
| Q1 24 | — | 45.7% |
营业利润率ABEOBDX
| Q4 25 | — | 10.5% | ||
| Q3 25 | — | 11.8% | ||
| Q2 25 | -5698.0% | 16.0% | ||
| Q1 25 | — | 10.4% | ||
| Q4 24 | — | 8.8% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | 12.1% | ||
| Q1 24 | — | 14.5% |
净利率ABEOBDX
| Q4 25 | — | 7.3% | ||
| Q3 25 | — | 8.4% | ||
| Q2 25 | 27208.3% | 10.4% | ||
| Q1 25 | — | 5.8% | ||
| Q4 24 | — | 5.9% | ||
| Q3 24 | — | 7.4% | ||
| Q2 24 | — | 9.8% | ||
| Q1 24 | — | 10.6% |
每股收益（稀释后）ABEOBDX
| Q4 25 | — | $1.34 | ||
| Q3 25 | $-0.10 | $1.71 | ||
| Q2 25 | $1.71 | $2.00 | ||
| Q1 25 | — | $1.07 | ||
| Q4 24 | — | $1.04 | ||
| Q3 24 | — | $1.37 | ||
| Q2 24 | — | $1.68 | ||
| Q1 24 | — | $1.85 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $207.1M | $740.0M |
| 总债务越低越好 | $19.8M | — |
| 股东权益账面价值 | $171.2M | $25.3B |
| 总资产 | $231.1M | $54.8B |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资ABEOBDX
| Q4 25 | — | $740.0M | ||
| Q3 25 | $207.1M | $641.0M | ||
| Q2 25 | $225.5M | $735.0M | ||
| Q1 25 | — | $667.0M | ||
| Q4 24 | — | $711.0M | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $4.5B | ||
| Q1 24 | — | $2.3B |
总债务ABEOBDX
| Q4 25 | — | — | ||
| Q3 25 | $19.8M | — | ||
| Q2 25 | $19.6M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ABEOBDX
| Q4 25 | — | $25.3B | ||
| Q3 25 | $171.2M | $25.4B | ||
| Q2 25 | $163.6M | $25.5B | ||
| Q1 25 | — | $25.2B | ||
| Q4 24 | — | $25.2B | ||
| Q3 24 | — | $25.9B | ||
| Q2 24 | — | $25.9B | ||
| Q1 24 | — | $25.6B |
总资产ABEOBDX
| Q4 25 | — | $54.8B | ||
| Q3 25 | $231.1M | $55.3B | ||
| Q2 25 | $246.2M | $54.9B | ||
| Q1 25 | — | $54.5B | ||
| Q4 24 | — | $54.7B | ||
| Q3 24 | — | $57.3B | ||
| Q2 24 | — | $55.6B | ||
| Q1 24 | — | $54.2B |
负债/权益比ABEOBDX
| Q4 25 | — | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-21.2M | $657.0M |
| 自由现金流经营现金流 - 资本支出 | $-23.7M | $549.0M |
| 自由现金流率自由现金流/营收 | — | 10.5% |
| 资本支出强度资本支出/营收 | — | 2.1% |
| 现金转化率经营现金流/净利润 | — | 1.72× |
| 过去12个月自由现金流最近4个季度 | — | $2.6B |
8季度趋势，按日历期对齐
经营现金流ABEOBDX
| Q4 25 | — | $657.0M | ||
| Q3 25 | $-21.2M | $1.4B | ||
| Q2 25 | $-18.8M | $1.2B | ||
| Q1 25 | — | $164.0M | ||
| Q4 24 | — | $693.0M | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $514.0M |
自由现金流ABEOBDX
| Q4 25 | — | $549.0M | ||
| Q3 25 | $-23.7M | $1.0B | ||
| Q2 25 | $-21.7M | $1.0B | ||
| Q1 25 | — | $35.0M | ||
| Q4 24 | — | $588.0M | ||
| Q3 24 | — | $882.0M | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $380.0M |
自由现金流率ABEOBDX
| Q4 25 | — | 10.5% | ||
| Q3 25 | — | 17.0% | ||
| Q2 25 | -5421.3% | 19.0% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | 11.4% | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | — | 22.4% | ||
| Q1 24 | — | 7.5% |
资本支出强度ABEOBDX
| Q4 25 | — | 2.1% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | 725.3% | 3.2% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 2.0% | ||
| Q3 24 | — | 5.4% | ||
| Q2 24 | — | 3.6% | ||
| Q1 24 | — | 2.7% |
现金转化率ABEOBDX
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | 2.75× | ||
| Q2 25 | -0.17× | 2.12× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | — | 2.29× | ||
| Q3 24 | — | 2.94× | ||
| Q2 24 | — | 2.66× | ||
| Q1 24 | — | 0.96× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABEO
暂无分部数据
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
